FCFrancisco Javier Caballero-Granado

Francisco Javier Caballero-Granado

*This is an algorithmically generated author record based on publicly available information.

Francisco Javier Caballero-Granado has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hormonal contraception and postmenopausal hormone therapy in Spain

    by Laura Costas, Víctor-Guillermo Sequera, Paloma Quesada, Jone M. Altzibar, Virginia Lope, Beatriz Pérez-Gómez, Yolanda Benavente, Vicente Martín, Delphine Casabonne, Claudia Robles, et al.

    This study aims to describe time trends in and patterns of use of hormonal contraception and postmenopausal hormone therapy and to identify factors associated with their use among Spanish women. We performed a cross-sectional analysis using data from 1,954 population controls (aged 24-85 y) in 12 provinces of Spain who were enrolled in the Multi Case-Control Spain study (2007-2013). Data were collected from a questionnaire conducted face-to-face by trained personnel. We collected information on sociodemographic factors, lifestyle, sleep patterns, reproductive history, and occupational history. Overall, 48.5% of Spanish women reported ever use of hormonal contraception, and 9.8% of women in the postmenopausal group reported use of postmenopausal hormone therapy. Younger cohorts used hormonal contraception for a longer period, whereas postmenopausal hormone therapy use dramatically dropped in the 2000s. Women with higher education levels (including education of partners) and smoking history were the most probable users of hormonal contraception, whereas inverse associations were observed among housewives, obese women, and nulliparous women. Postmenopausal hormone therapy use was associated with a surgical or therapeutic cause of menopause and with occupational history of rotating shifts. In this Spanish population, several demographic, lifestyle, occupational, and reproductive factors are associated with use of hormonal compounds. Characterizing hormonal users and monitoring trends in the use of these hormonal compounds are essential from a public health perspective.


  • Open Access

    Association of diabetes and diabetes treatment with incidence of breast cancer

    by Esther García-Esquinas, Elisabeth Guinó, Gemma Castaño-Vinyals, Beatriz Pérez-Gómez, Javier Llorca, Jone M. Altzibar, Rosana Peiró-Pérez, Vicente Martín, Concepción Moreno-Iribas, Adonina Tardón, et al.

    Aims The aim of this study was to evaluate the association of diabetes and diabetes treatment with risk of postmenopausal breast cancer. Methods Histologically confirmed incident cases of postmenopausal breast (N = 916) cancer were recruited from 23 Spanish public hospitals. Population-based controls (N = 1094) were randomly selected from primary care center lists within the catchment areas of the participant hospitals. ORs (95 % CI) were estimated using mixed-effects logistic regression models, using the recruitment center as a random effect term. Breast tumors were classified into hormone receptor positive (ER+ or PR+), HER2+ and triple negative (TN). Results Diabetes was not associated with the overall risk of breast cancer (OR 1.09; 95 % CI 0.82–1.45), and it was only linked to the risk of developing TN tumors: Among 91 women with TN tumors, 18.7 % were diabetic, while the corresponding figure among controls was 9.9 % (OR 2.25; 95 % CI 1.22–4.15). Regarding treatment, results showed that insulin use was more prevalent among diabetic cases (2.5 %) as compared to diabetic controls (0.7 %); OR 2.98; 95 % CI 1.26–7.01. They also showed that, among diabetics, the risk of developing HR+/HER2− tumors decreased with longer metformin use (ORper year 0.89; 95 % CI 0.81–0.99; based on 24 cases and 43 controls). Conclusion This study reinforces the need to correctly classify breast cancers when studying their association with diabetes. Given the low survival rates in women diagnosed with TN breast tumors and the potential impact of diabetes control on breast cancer prevention, more studies are needed to better characterize this association.


  • FRI0533 Primary Pyomyositis in Children: A Retrospective Review of 25 Cases

    by D. Clemente, I. Martinez, M. de la Torre, F.J. Caballero, J.C. Lopez Robledillo

    Background Primary pyomyositis is a rare condition in children that should be included in the differential diagnosis of musculoskeletal infections. Objectives To describe the clinical features of pyomyositis as well as its diagnostic and therapeutic approach. Methods A descriptive and retrospective study was performed by reviewing medical records of patients admitted to our hospital from January 1996 to July 2013 with a diagnosis of primary pyomyositis. Results A total of 25 patients (16 men, 9 women) aged between one month and 14 years (median age 2 years) were registered. Two peaks of incidence have been found in the months of July and October. The most frequent clinical manifestations were the presence of local pain (24 patients), fever (18 patients), local swelling (9 patients) and skin rash (7 patients). Predisposing factors in 8 patients (1 strenuous exercise, 4 trauma, 3 intramuscular injections) were found. The primary site was pelvic muscles or lower extremities (20 patients). In laboratory results, we found the presence of leukocytosis, with an average value of 12,936±5.753/uL leukocytes, total neutrophils 4.659/uL ±7.350), ESR of 55±28 mm) and PCR 8±6 mg/dL). CPK was normal in 5 out of 6 patients who were requested. Laboratory results were positive for Staphylococcus aureus (7 patients), Salmonella no tiphy (1 patient) and Bacteroides fragillis (1 patient). Ultrasound suggested the diagnosis in 11 cases and magnetic resonance imaging support the diagnosis in all cases. All patients received intravenous antibiotic therapy (mean duration 11 days) followed by oral antibiotic therapy (mean duration 23 days). 9 patients suffered complications as abscess formation, 3 need abscess aspiration and one of them required surgical drainage. None of our patients had residual functional limitations. Conclusions It is important to have a high index of suspicion for pyomyositis in patients with fever and musculoskeletal pain at an early stage in order to initiate start appropriate antibiotic treatment against Staphylococcus aureus. Although ESR and ultrasound may be useful, it is necessary to complement with magnetic resonance imaging in order to support the diagnosis in all cases. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4467


  • Pupila de Adie

    by Eduardo Durán-Ferreras, Antonia Idígoras-Hurtado, Javier Caballero-Granado


  • Ceguera bilateral aislada transitoria asociada a infarto cerebral occipital unilateral

    by Eduardo Durán-Ferreras, Juan Ignacio Ramos-Clemente Romero, Francisco Javier Caballero-Granado

  • Aproximación clínica y terapéutica a las infecciones de las vías respiratorias. Documento de Consenso de la Sociedad Andaluza de Enfermedades Infecciosas y de la Sociedad Andaluza de Medicina Familiar y Comunitaria

    by Elisa Cordero Matía, Juan de Dios Alcántara Bellón, Javier Caballero Granado, Javier de la Torre Lima, José Antonio Girón González, Carmen Lama Herrera, Ana Morán Rodríguez, Ángel Zapata López


  • Aproximación clínica y terapéutica a las infecciones de las vías respiratorias. Documento de Consenso de la Sociedad Andaluza de Enfermedades Infecciosas y de la Sociedad Andaluza de Medicina Familiar y Comunitaria

    by Elisa Cordero Matía, Juan de Dios Alcántara Bellón, Javier Caballero Granado, Javier de la Torre Lima, José Antonio Girón González, Carmen Lama Herrera, Ana Morán Rodríguez, Ángel Zapata López


  • Incidence of and Factors Associated with Hepatocellular Carcinoma among Hepatitis C Virus and Human Immunodeficiency Virus Coinfected Patients with Decompensated Cirrhosis

    by José A. García-García, Manuel Romero-Gómez, José A. Girón-González, Robin Rivera-Irigoin, Julián Torre-Cisneros, José L. Montero, Mercedes González-Serrano, Raúl J. Andrade, Manuela Aguilar-Guisado, Israel Grilo, et al.

    We compared the incidence of and factors associated with hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)-monoinfected subjects and human immunodeficiency virus (HIV)/HCV-coinfected individuals, both with decompensated cirrhosis. In a retrospective study, a cohort of 180 individuals with HIV coinfection and 1037 HCV-monoinfected patients with decompensated HCV-related cirrhosis from eight centres in Spain were analyzed. HCC was found in 234 (23%) HCV-monoinfected subjects and in four (2%) HIV-coinfected subjects (p < 0.001). At the time of the first hepatic decompensation, 188 (17%) and 4 (2%) (p < 0.001) patients in the former and in the latter group, respectively, showed HCC. Fifty-four (11%) patients without HCC at baseline developed such a disease during follow-up. There were no incident cases among the HIV-coinfected population. The density of incidence (95% IC) of HCC in HIV/HCV-coinfected and HCV-monoinfected patients was 0 (0–1.70) and 3.31 (2.70–4.64) cases per 100 person-years (p < 0.001), respectively. Lack of HIV infection [adjusted odds risk (AOR) (95% IC) = 16.7 (3.9–71.1)] and high alanine aminotransferase levels [AOR (95% IC) = 2.5 (1.1–5)] were the only two independent predictors of the emergence of HCC. In the group of patients in whom the date of HCV infection could be estimated, the time elapsed until HCC diagnosis was shorter among HIV-coinfected subjects. The incidence of HCC in patients with HCV-related cirrhosis after the first hepatic decompensation is lower in HIV-coinfected patients. This is probably due to the fact that HIV infection shortens the survival of HCV-coinfected patients with end-stage liver disease to such an extent that HCC not had a chance to emerge.


  • Open Access

    Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C

    by JosÉ A. Mira, Juan MacÍAs, JosÉ A. GirÓN-GonzÁLez, Dolores Merino, Mercedes GonzÁLez-Serrano, Manuel E. JimÉNez-MejÍAs, Francisco J. Caballero-Granado, JuliÁN Torre-Cisneros, Alberto TerrÓN, Mark I. Becker, et al.

    Objectives: To determine the incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among human immunodeficiency virus/hepatitis C virus (HIV/HCV)-coinfected patients with known stage of liver fibrosis. Methods: All HIV/HCV-coinfected patients were monitored for a period of 12 months after starting nelfinavir-containing regimens and, with an available liver biopsy, were included in a retrospective study. Results: A total of 82 patients were included in the study. Nine (10.9%) HIV/HCV-coinfected patients showed an episode of severe hepatotoxicity during the study period. Eight (9.8%) individuals showed grade 3 or 4 change in levels of serum alanine aminotransferase and one subject presented with an event of decompensated liver cirrhosis. Six (18.2%) of 33 patients with advanced liver fibrosis and three (6%) of 49 individuals without advanced liver fibrosis showed an episode of severe hepatotoxicity (P = 0.1). In the multivariate analysis, only nevirapine use during nelfinavir therapy [adjusted odds ratio (AOR) 8.9; 95% confidence interval (CI), 1.4–54.1; P = 0.01] was independently associated with risk of development of severe liver toxicity. Conclusions: The incidence of severe hepatotoxicity of nelfinavir-containing regimens is low among HIV/HCV-coinfected patients with known stage of liver fibrosis. In addition, our findings show that concomitant nevirapine use is associated with an increased risk of severe hepatotoxicity in these subjects. Likewise, the proportion of severe liver toxicity tended to be higher in individuals with advanced liver fibrosis.


  • Open Access

    Efficacy of β-lactams against experimental pneumococcal endocarditis caused by strains with different susceptibilities to penicillin

    by Cristina Pichardo, Fernando Docobo-Pérez, Maria E. Pachón-Ibáñez, Manuel E. Jiménez-Mejías, Andrés García-Curiel, F. Javier Caballero-Granado, Ignacio Moreno-Maqueda, Jerónimo Pachón

    Objectives: To compare the in vitro and in vivo activity of penicillin, cefotaxime and ceftriaxone, using three strains of Streptococcus pneumoniae with different susceptibilities to penicillin (MICs of 0.015, 0.25 and 2 mg/L, respectively). Methods: Time–kill curves and an experimental model of endocarditis in rabbits. Results: Penicillin was efficacious in clearing bacteria from vegetations and blood irrespective of whether infections were caused by penicillin-susceptible or penicillin-resistant strains (P < 0.01 with respect to control groups). The same efficacy was shown with cefotaxime and ceftriaxone. Comparing the results of the in vivo model with those obtained in time–kill curves, penicillin showed the best results. Conclusions: These results confirm that penicillin is efficacious in the treatment of pneumococcal infections, including those produced by strains with MICs ≤ 2 mg/L (with the exception of pneumococcal meningitis). These results also suggest that the breakpoints to define susceptibility and resistance of S. pneumoniae to penicillin must be reviewed, as has been done with amoxicillin and third-generation cephalosporins.